证券日报网讯 1月20日，兴齐眼药在互动平台回答投资者提问时表示，公司当前主营业务聚焦于国内市 场，相关海外合作事宜尚处于沟通洽谈阶段，达到信息披露节点时，公司将依规公告。未来，公司将继 续通过加大研发投入、优化产品结构、提高生产效率、加强市场开拓力度等方式持续提升市场份额，为 投资者创造长期价值。 （编辑 丛可心） ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

Core Viewpoint - The competition among domestic pharmaceutical companies in the field of myopia prevention drugs is intensifying, with Xingqi Eye Medicine leading the market by obtaining multiple approvals for atropine eye drops and advancing new drug trials [2][3][4]. Group 1: Product Approvals and Market Position - Xingqi Eye Medicine was the first in China to receive approval for 0.01% atropine eye drops in March 2024, establishing a competitive edge in the myopia prevention market [2][4]. - The company has also received approvals for 0.02% and 0.04% concentrations of atropine eye drops, enhancing its market position through a gradient concentration strategy [2][4]. - The newly approved SQ-24071 eye drops for clinical trials represent a significant milestone in the drug development process, indicating the transition from laboratory research to human testing [2][3]. Group 2: Financial Performance - Since the launch of its atropine eye drops, Xingqi Eye Medicine has experienced substantial revenue growth, with a 32.42% increase in revenue and a 40.84% increase in net profit for 2024 compared to 2023 [4]. - In the first three quarters of 2025, the company reported a 32.27% year-on-year increase in revenue and a remarkable 105.98% increase in net profit [5]. Group 3: Industry Trends and Future Outlook - The rising incidence of myopia in China, driven by excessive use of electronic devices and poor eye care habits, has created a significant public health issue, prompting increased competition among pharmaceutical companies [3]. - The approval of SQ-24071 eye drops signifies a shift in the myopia prevention market from single-product competition to a comprehensive strategy involving product matrices and service ecosystems [5].

Core Viewpoint - The company, Xingqi Eye Medicine, has received approval from the National Medical Products Administration for the clinical trial of its eye drop product SQ-24071, aimed at delaying myopia progression in children and adolescents [1]. Group 1 - The announcement was made on January 19, indicating the company's ongoing commitment to developing innovative treatments for eye health [1]. - SQ-24071 is classified as a modified new drug of chemical drugs category 2.2 and 2.4, highlighting its potential significance in the pharmaceutical market [1]. - The clinical trial approval marks a critical step in the product's development, which could address a growing concern regarding myopia in younger populations [1].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to delay the progression of myopia in children and adolescents [1] Group 1 - SQ-24071 eye drops are classified as a modified new drug of chemical drug category 2.2; 2.4 [1] - The company has completed various studies, including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value for SQ-24071 eye drops [1]

智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局签发的关于SQ-24071滴眼 液的《药物临床试验批准通知书》。SQ-24071滴眼液为公司研发的化学药品2.2;2.4类改良型新药。临床 拟用于延缓儿童及青少年的近视进展。根据改良型新药的有关要求,公司已经完成SQ-24071滴眼液药学 及非临床药理毒理学等多方面的研究，研究结果表明SQ-24071滴眼液具有良好的安全性及临床开发价 值。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] Group 1 - SQ-24071 eye drops are classified as a modified new drug of chemical drugs category 2.2 and 2.4 [1] - The company has completed various studies on SQ-24071, including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value [1] - There are currently no similar eye drop formulations available in the domestic and international markets [1]

Core Viewpoint - The company, Xingqi Eye Medicine, has received approval from the National Medical Products Administration for clinical trials of SQ-24071 eye drops, aimed at delaying the progression of myopia in children and adolescents [1] Company Summary - Xingqi Eye Medicine announced on January 19 that it has obtained a clinical trial approval notice for SQ-24071 eye drops from the National Medical Products Administration [1]

Group 1 - The core point of the article is that Xingqi Eye Pharmaceutical (300573) has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] - SQ-24071 is classified as a chemical drug of category 2.2; 2.4, indicating it is a modified new drug [1] - The approval signifies a potential advancement in the treatment options available for myopia, a growing concern among younger populations [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-002 沈阳兴齐眼药股份有限公司 申请人：沈阳兴齐眼药股份有限公司 关于SQ-24071滴眼液获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局签发的关于 SQ-24071 滴眼液的《药物临床试验批准通知书》。现将相关情 况公告如下： 一、药品基本情况 药品名称：SQ-24071 滴眼液 适应症：拟用于延缓儿童及青少年的近视进展。 通知书编号：2026LP00170、2026LP00171、2026LP00172、2026LP00173 剂型：滴眼液 申请事项：境内生产药品注册临床试验 注册分类：化学药品 2.2；2.4 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 14 日受理的 SQ-24071 滴眼液符合药品注册的有关要求，同意开展临床 试验。 二、药品研发及其他情况 SQ-24071 滴眼液为我公司研发的化学药品 2.2；2.4 类改良型新药。临 ...